Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vardenafil
Drug ID BADD_D02335
Description Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.
Indications and Usage Used for the treatment of erectile dysfunction
Marketing Status approved
ATC Code G04BE09
DrugBank ID DB00862
KEGG ID D08668
MeSH ID D000069058
PubChem ID 135400189
TTD Drug ID D0C9SY
NDC Product Code 33342-203; 46708-235; 70710-1070; 70771-1048; 51407-174; 70771-1050; 71610-477; 71610-643; 70710-1069; 47621-303; 70710-1068; 70771-1047; 70710-1071; 62332-235; 70771-1049
UNII UCE6F4125H
Synonyms Vardenafil Dihydrochloride | Dihydrochloride, Vardenafil | Vardenafil Hydrochloride Anhydrous | Anhydrous, Vardenafil Hydrochloride | Hydrochloride Anhydrous, Vardenafil | Vardenafil | 1-(((3-(3,4-dihydro-5-methyl)-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine | Levitra | Vardenafil Hydrochloride Trihydrate | Hydrochloride Trihydrate, Vardenafil | Trihydrate, Vardenafil Hydrochloride | Vardenafil Hydrochloride | Hydrochloride, Vardenafil
Chemical Information
Molecular Formula C23H32N6O4S
CAS Registry Number 224785-90-4
SMILES CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypoaesthesia17.02.06.023; 23.03.03.081--Not Available
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Influenza11.05.03.001; 22.07.02.001--Not Available
Influenza like illness08.01.03.010--
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intraocular pressure increased13.07.04.002--Not Available
Lacrimation increased06.08.02.004--
Laryngeal oedema22.04.02.001; 10.01.05.003; 23.04.01.005--
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Menopausal symptoms21.02.02.002--Not Available
Muscle rigidity15.05.04.001; 17.05.02.005--Not Available
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nervous system disorder17.02.10.001--Not Available
Ocular hyperaemia06.04.05.004--Not Available
Oedema mucosal08.01.06.012--Not Available
Oesophagitis07.08.05.001--
Optic ischaemic neuropathy06.07.03.001; 24.04.10.001; 17.04.05.006--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages